| Title: |
751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial |
| Authors: |
Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J-W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; Tognon, G.; Chudecka-Glaz, A.M.; Berger, R.; Lheureux, S.; Henry, S.; Burges, A.; Wenham, R.M.; Nishio, S.; Marshall, L.; Harter, P. |
| Contributors: |
AstraZeneca |
| Source: |
Annals of Oncology ; volume 35, page S570-S571 ; ISSN 0923-7534 |
| Publisher Information: |
Elsevier BV |
| Publication Year: |
2024 |
| Collection: |
ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/j.annonc.2024.08.812 |
| Availability: |
http://dx.doi.org/10.1016/j.annonc.2024.08.812; https://api.elsevier.com/content/article/PII:S0923753424023317?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0923753424023317?httpAccept=text/plain |
| Rights: |
https://www.elsevier.com/tdm/userlicense/1.0/ ; https://www.elsevier.com/legal/tdmrep-license |
| Accession Number: |
edsbas.F08F211D |
| Database: |
BASE |